307 related articles for article (PubMed ID: 27296533)
21. Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers.
Drollmann A; Brown M; Sechaud R; Perry S; Hara H; Jones I; Febbraro S
Int J Clin Pharmacol Ther; 2014 May; 52(5):369-80. PubMed ID: 24569129
[TBL] [Abstract][Full Text] [Related]
22. Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes.
Namba Y; Togo S; Tulafu M; Kadoya K; Nagahama KY; Taka H; Kaga N; Orimo A; Liu X; Takahashi K
Respir Res; 2017 Mar; 18(1):46. PubMed ID: 28284212
[TBL] [Abstract][Full Text] [Related]
23. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
Gavaldà A; Ramos I; Carcasona C; Calama E; Otal R; Montero JL; Sentellas S; Aparici M; Vilella D; Alberti J; Beleta J; Miralpeix M
Pulm Pharmacol Ther; 2014 Aug; 28(2):114-21. PubMed ID: 24928173
[TBL] [Abstract][Full Text] [Related]
24. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A; Babu KS; Morjaria JB
Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
[TBL] [Abstract][Full Text] [Related]
25. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
Montuschi P; Ciabattoni G
J Med Chem; 2015 May; 58(10):4131-64. PubMed ID: 25587755
[TBL] [Abstract][Full Text] [Related]
26. [Role of bronchodilators in therapy for COPD-mechanisms of LABA and LAMA on airway smooth muscle].
Kume H
Nihon Rinsho; 2016 May; 74(5):813-9. PubMed ID: 27254952
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi.
Calzetta L; Rogliani P; Facciolo F; Rendina E; Cazzola M; Matera MG
Eur J Pharmacol; 2017 Oct; 812():147-154. PubMed ID: 28716723
[TBL] [Abstract][Full Text] [Related]
28. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone.
Calzetta L; Page CP; Spina D; Cazzola M; Rogliani P; Facciolo F; Matera MG
J Pharmacol Exp Ther; 2013 Sep; 346(3):414-23. PubMed ID: 23766543
[TBL] [Abstract][Full Text] [Related]
29. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.
Cazzola M; Calzetta L; Ora J; Puxeddu E; Rogliani P; Matera MG
Respir Med; 2015 Oct; 109(10):1305-11. PubMed ID: 26303336
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells.
Yamaya M; Nishimura H; Deng X; Sugawara M; Watanabe O; Nomura K; Shimotai Y; Momma H; Ichinose M; Kawase T
Respir Investig; 2020 May; 58(3):155-168. PubMed ID: 32094077
[TBL] [Abstract][Full Text] [Related]
31. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita N; Kaneko T
Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
[TBL] [Abstract][Full Text] [Related]
32. [The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Ulrik CS
Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294211
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
Aparici M; Gómez-Angelats M; Vilella D; Otal R; Carcasona C; Viñals M; Ramos I; Gavaldà A; De Alba J; Gras J; Cortijo J; Morcillo E; Puig C; Ryder H; Beleta J; Miralpeix M
J Pharmacol Exp Ther; 2012 Aug; 342(2):497-509. PubMed ID: 22588259
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
Battram C; Charlton SJ; Cuenoud B; Dowling MR; Fairhurst RA; Farr D; Fozard JR; Leighton-Davies JR; Lewis CA; McEvoy L; Turner RJ; Trifilieff A
J Pharmacol Exp Ther; 2006 May; 317(2):762-70. PubMed ID: 16434564
[TBL] [Abstract][Full Text] [Related]
35. Indacaterol/Glycopyrronium in the Treatment of Severe Respiratory Failure: Marked Improvement of Respiratory Failure in a Few Weeks - A Case Report.
Pistelli R; Castriotti MR; Panico L
Respiration; 2018; 95 Suppl 1():19-21. PubMed ID: 29705782
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.
Calzetta L; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():168-73. PubMed ID: 25981302
[TBL] [Abstract][Full Text] [Related]
39. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD.
Schachter EN
Drugs Today (Barc); 2013 Jul; 49(7):437-46. PubMed ID: 23914352
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol.
Aparici M; Gavaldà A; Ramos I; Carcasona C; Otal R; Fernández-Blanco JA; Montero JL; García VM; López R; De Alba J; Doe C; Puig C; Vilella D; Miralpeix M
Eur J Pharmacol; 2016 Jan; 770():61-9. PubMed ID: 26656755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]